Key facts
- This page summarizes Anila Lingamneni's Form 4 filing for HAEMONETICS CORP (HAE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Jul 2024, 16:27.
Anila Lingamneni - 11 Jul 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Reporting relationship
- EVP, Chief Technology Officer
- Issuer ticker
- HAE
- Reported as of
- 11 Jul 2024
- Net transaction value
- -$199,350
- SEC form
- 4
- Accepted by SEC
- 15 Jul 2024, 16:27:53 UTC
- Prior SEC filing
- 29 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas V. Powers, attorney-in-fact for Ms. Lingamneni
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Anila Lingamneni filed Form 4 for HAEMONETICS CORP (HAE) on 15 Jul 2024.
Change
- Previous filing in this sequence was filed on 29 May 2024.
- Current net transaction value: -$199,350.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HAE
transaction
Common Stock
Sale
- Transaction value
- -$192,240
- Shares
- -2,136
- Change %
- -9.1%
- Price
- $90.00
- Shares after
- 21,410
- Date
- 11 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
HAE
transaction
Common Stock
Sale
- Transaction value
- -$7,110
- Shares
- -79
- Change %
- -0.37%
- Price
- $90.00
- Shares after
- 21,331
- Date
- 12 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).
Footnote F2
This number includes unvested restricted stock units previously reported.